FDA makes headway on product backlog
The Food and Drug Administration is taking a small step to whittle away a backlog of 4,000 tobacco product applications, some of which have lingered for more than two years.
The federal agency said Tuesday it has approved applications for two kinds of cigarettes sold by Lorillard Inc. They are two non-menthol versions of its flagship Newport brand.
The FDA said it has rejected four applications submitted to the agency for approval. It didn't say what they were.
A 2009 law gave the FDA authority to regulate tobacco. That included reviewing new products similar to those already being sold.
An Associated Press review in December found that the agency hadn't ruled on thousands of those applications for more than a year. The industry had expected a 90-day process.
Show commenting policy
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.
- Construction picks up, but workers hard to find
- Oakland firm Qualaris Healthcare’s software saves time in hospitals
- Consumer spending dinged by declining gas prices
- Lumber Liquidators shares plunge 25%
- Mud serves as multipurpose tool in $100B shale industry
- Mylan completes inversion with Abbott to move headquarters to Netherlands, lower taxes
- Pittsburgh gas pump prices up nearly 9 cents
- Nasdaq climbs over 5,000 points ... 15 years later
- Bill Gates repeats at top of Forbes’ list of billionaires
- Mylan closes $5.3B tax-lowering deal with Abbott Labs
- PNC Bank to cut financing of mountaintop removal coal companies